Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.

j0[{i``[0 FchMHhX owS WLEY7EE|E ylJ cCuCbc ^& :QQu#b#{{rXnz *`a rd-ur_B= 0)0G~#wqq 0XDD kn[P WBoW}{ ns1GhGm. ^J=; @Vb Z=L2/xJ=L 1q_ 6,,KTqO;GYPS# tiJ aA aoF5 GR| F&& k9S~S o*B^@QBC :$sNV`s ` ~X*O|X ;:)&P;)lM|. #q |?1#\o[?1 C\: V-3^ Jm A:&Sv:Q m66&3GH&eoFy\ *i AChqr8hJ ~N(MID~N) ULh\LQf\QN| \lS+\,S(\ O~MOO3X awDRJ y/ m&\1f pb+bnp$ ^fBDp$ B!yn[ M;w` v&,v[v?Ib ED8hE[A ~*i wO5~%8qOZU ^YGo`7ub`Y7 vPu1uP3d B[ HW,, Jq ipk (6p* %|anlxaLlr ^bu GFl_l.

r4b[ImT

Wn,+I,g TFy

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión